Novo Nordisk CEO Mike Doustdar. CNBC Novo Nordisk CEO Mike Doustdar on Wednesday said the company is aiming to capture around 15 million new patients, at least initially, when Medicare starts covering obesity treatments for the first time later this year. Around 67 million Americans are covered by Medicare, but “when you take a look…
A researcher works in the lab at the Moderna Inc. headquarters in Cambridge, Massachusetts, US, on Tuesday, March 26, 2024. Adam Glanzman | Bloomberg | Getty Images The Food and Drug Administration has refused to start a review of Moderna‘s application for its experimental flu shot, the company announced Tuesday, in another sign of the…
A pedestrian walks by a CVS store in Greenbrae, California, on July 31, 2025. Justin Sullivan | Getty Images CVS Health on Tuesday reported fourth-quarter earnings and revenue that beat estimates and reaffirmed the 2026 profit guidance that impressed investors, signaling steady progress in the health-care giant’s turnaround plan. “’24 was a tough year for…
The logo of pharmaceutical company Novo Nordisk is displayed in front of its offices in Bagsvaerd, Copenhagen, Denmark, February 4, 2026. Tom Little | Reuters Novo Nordisk on Monday said it is suing online telehealth provider Hims & Hers for mass marketing cheaper, unapproved copies of the drugmaker’s new Wegovy obesity pill and injections in…
Piotr Swat | Lightrocket | Getty Images Hims & Hers on Saturday said that it will pull its copycat weight-loss pill off the market after sparking controversy and threats of legal action earlier this week. “Since launching the compounded semaglutide pill on our platform, we’ve had constructive conversations with stakeholders across the industry,” the telehealth…
U.S. President Donald Trump makes an announcement from the Oval Office at the White House in Washington, D.C., U.S. Nov. 6, 2025. Jonathan Ernst | Reuters President Donald Trump on Thursday is slated to announce the launch of TrumpRx – a direct-to-consumer website that is key to his administration’s efforts to lower prescription drug costs…
The Eli Lilly and Novo Nordisk logos. Mike Blake | Tom Little | Reuters It’s a tale of two drugmakers in the red-hot obesity drug market. Both Novo Nordisk and Eli Lilly are grappling with lower prices in the U.S., but their 2026 outlooks are diverging sharply: While Novo is bracing for a sales decline,…
Eli Lilly on Wednesday posted fourth-quarter earnings and revenue and 2026 guidance that blew past estimates, as demand for its blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro soars. The pharmaceutical giant anticipates its 2026 revenue will come in between $80 billion and $83 billion. Analysts expected revenue of $77.62 billion, according to LSEG. …
Smith Collection | Archive Photos | Getty Images Pfizer on Tuesday said its experimental obesity drug, which it acquired through Metsera, drove solid weight loss when taken once a month in a mid-stage trial. Patients with obesity or who are overweight lost up to 12.3% of their weight compared with placebo at week 28 in…
Merck on Tuesday reported fourth-quarter earnings and revenue that topped estimates on strong demand for its cancer immunotherapy Keytruda and some newer products. But the company posted a modest 2026 outlook that fell short of Wall Street’s expectations as it prepares for a few drugs to lose patent protection later this year and face generic…